August 7, 2015 : Episode 1

Video

Lenvatinib Breakthrough Designation, New Drug Applications for NSCLC, STS, and More

Related Videos
David A. Braun, MD, PhD
David A. Braun, MD, PhD
Bradley McGregor, MD,
Ewa Kalinka, MD, PhD
Ami Umesh Badami, MD, medical oncologist, Endeavor Health Medical Group
Thomas Westbrook, MD, assistant professor, Department of Internal Medicine, Rush University
Benjamin P. Levy, MD
Related Content
Alexander Watson, MD, DPhil, FRCPC
January 23rd 2025

Driver-Positive Tumor Frequency Decreases With Increasing Copy Number Gain in NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

NSCLC | Image Credit: © Axel Kock – stock.adobe.com
January 21st 2025

First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

Limertinib for EGFR T790M+ NSCLC | Image Credit: © catalin – stock.adobe.com
January 17th 2025

Limertinib Wins Approval in China for EGFR T790M+ NSCLC